Transgene operates under a business model based around its expertise and fully integrated capabilities for the discovery and development of novel viral vector-based targeted immunotherapeutics.
• Therapeutic partnering strategy: out-licensing to major pharmaceutical partners
Transgene uses its in-house discovery and development resources to discover, evaluate pre-clinically, and then test in human clinical studies a wide range of novel immunotherapeutics. The company focuses on two therapeutic areas – oncology and infectious diseases.
Transgene may seek to partner these programs with leading pharmaceutical partners in the relevant disease areas as they reach key pre-clinical or clinical development milestones.
• R&D collaborations and Open Innovation strategy with major pharmaceutical partners and/or specialized biotechs
Transgene has unique expertise in developing targeted immunotherapeutics utilizing a wide range of viral vectors. This expertise, combined with a comprehensive infrastructure for drug discovery, development, and manufacturing, including formulation and process development, makes a powerful drug creation platform.
Transgene is therefore ideally placed to become the immunotherapeutic partner of choice for pharmaceutical companies looking to enter the field of viral vector-based immunotherapeutics or to bolster their internal efforts in this area.
Transgene’s model for R&D collaborations is extremely flexible to meet its partners’ needs, including:
– Utilization of a variety of viral vector platforms, including MVA, oncolytic vaccinia and adenovirus platforms.
– R&D in the areas of infectious disease and oncology.
– Collaborations based on different R&D concepts.
These range from de novo therapeutic discovery and development of immunotherapeutics for use as a standalone therapy or in combination with other treatments, to vectorization of a partner’s therapeutic molecule within a single virus-based therapeutic to provide a) more effective targeting, b) production of the partner’s therapeutic “in-situ” and c) potent “single administration” polyvalent therapies.
– Ability to take programs to different stages of development
Transgene’s capabilities run from discovery through clinical proof-of-concept, including manufacturing.
• Complementary In-licensing strategy to broaden our clinical development portfolio
Transgene also pursues a variety of collaborative models to enhance its competitive position at the forefront of the existing field of viral vector-based targeted immunotherapeutics. We are interested in in-licensing attractive clinical-stage viral-based immunotherapeutic programs to broaden our portfolio and better manage our franchise life cycle. For example, we have a strategic partnership with SillaJen to develop and commercialize Pexa-Vec for the treatment of solid tumors in Europe.